| Two phase 3 trials of dupilumab versus placebo in atopic dermatitis EL Simpson, T Bieber, E Guttman-Yassky, LA Beck, A Blauvelt, MJ Cork, ... New England Journal of Medicine 375 (24), 2335-2348, 2016 | 1852 | 2016 |
| Pharmacogenetics of psoriasis: HLA‐Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker … M Talamonti, E Botti, M Galluzzo, M Teoli, G Spallone, M Bavetta, ... British Journal of Dermatology 169 (2), 458-463, 2013 | 184 | 2013 |
| Italian guidelines on the systemic treatments of moderate‐to‐severe plaque psoriasis P Gisondi, G Altomare, F Ayala, F Bardazzi, L Bianchi, A Chiricozzi, ... Journal of the European Academy of Dermatology and Venereology 31 (5), 774-790, 2017 | 183 | 2017 |
| Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics M Papoutsaki, MS Chimenti, A Costanzo, M Talamonti, A Zangrilli, ... Journal of the American Academy of Dermatology 57 (2), 269-275, 2007 | 141 | 2007 |
| Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study C Patruno, M Napolitano, G Argenziano, K Peris, M Ortoncelli, ... Journal of the European Academy of Dermatology and Venereology 35 (4), 958-964, 2021 | 85 | 2021 |
| Italian Guidelines in diagnosis and treatment of alopecia areata A Rossi, M Muscianese, BM Piraccini, M Starace, M Carlesimo, ... Giornale Italiano di Dermatologia e Venereologia 154 (6), 609-623, 2019 | 76 | 2019 |
| Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation M Galluzzo, M Talamonti, C De Simone, S D’Adamio, G Moretta, ... Expert opinion on biological therapy 18 (7), 727-735, 2018 | 69 | 2018 |
| Role of the HLA‐C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients M Talamonti, M Galluzzo, JM Van Den Reek, EM de Jong, JLW Lambert, ... British Journal of Dermatology 177 (2), 489-496, 2017 | 69 | 2017 |
| Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry. NL Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M ... J Am Acad Dermatol 70 (2), 257-62, 2014 | 66 | 2014 |
| Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study M Galluzzo, L Tofani, P Lombardo, A Petruzzellis, D Silvaggio, CG Egan, ... Journal of Clinical Medicine 9 (7), 2170, 2020 | 62 | 2020 |
| Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature G Caldarola, F Pirro, A Di Stefani, M Talamonti, M Galluzzo, S D’Adamio, ... Expert opinion on biological therapy 20 (6), 665-672, 2020 | 62 | 2020 |
| IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis M Galluzzo, AN Boca, E Botti, C Potenza, G Malara, P Malagoli, S Vesa, ... Dermatology 232 (2), 230-236, 2016 | 61 | 2016 |
| Pruritus characteristics in a large Italian cohort of psoriatic patients G Damiani, S Cazzaniga, RR Conic, L Naldi, Psocare Registry Network, ... Journal of the European Academy of Dermatology and Venereology 33 (7), 1316-1324, 2019 | 59 | 2019 |
| Efalizumab M Talamonti, G Spallone, A Di Stefani, A Costanzo, S Chimenti Expert opinion on drug safety 10 (2), 239-251, 2011 | 58 | 2011 |
| HLA-C* 06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up M Talamonti, M Galluzzo, S Chimenti, A Costanzo Journal of the American Academy of Dermatology 74 (2), 374-375, 2016 | 55 | 2016 |
| Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational study M Talamonti, M Galluzzo, A Chiricozzi, P Quaglino, G Fabbrocini, ... Expert Opinion on Biological Therapy 21 (2), 271-277, 2021 | 52 | 2021 |
| Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. NL Gisondi P, Cazzaniga S, Chimenti S, Maccarone M, Picardo M, Girolomoni G Br J Dermat 172 (6), 1613-20., 2015 | 51 | 2015 |
| Treat-to-target approach for the management of patients with moderate-to-severe plaque psoriasis: consensus recommendations P Gisondi, M Talamonti, A Chiricozzi, S Piaserico, P Amerio, A Balato, ... Dermatology and Therapy 11, 235-252, 2021 | 50 | 2021 |
| Alexithymia and plaque psoriasis: preliminary investigation in a clinical sample of 250 patients M Talamonti, M Galluzzo, S Servoli, S D'Adamio, L Bianchi Dermatology 232 (6), 648-654, 2017 | 50 | 2017 |
| Effectiveness and safety of long-term dupilumab treatment in elderly patients with atopic dermatitis: a multicenter real-life observational study C Patruno, G Fabbrocini, G Longo, G Argenziano, SM Ferrucci, L Stingeni, ... American Journal of Clinical Dermatology 22, 581-586, 2021 | 49 | 2021 |
Marco GalluzzoDermatology Unit - Department of Systems Medicine, University of Rome "Tor Vergata"在 uniroma2.it 的电子邮件经过验证
